Chronic GVHD characteristics at baseline
| NIH Consensus score . | None . | Mild . | Moderate . | Severe . |
|---|---|---|---|---|
| Skin, n (%) | 4 (17) | 2 (8) | 12 (50) | 6 (25) |
| Mouth, n (%) | 5 (21) | 9 (37) | 10 (42) | 0 (0) |
| Eyes, n (%) | 14 (58) | 6 (25) | 3 (13) | 1 (4) |
| Gastrointestinal tract, n (%) | 16 (67) | 4 (17) | 4 (17) | 0 (0) |
| Liver, n (%) | 12 (50) | 0 (0) | 5 (21) | 7 (29) |
| Lung, n (%) | 14 (58) | 5 (21) | 4 (17) | 1 (4) |
| Joint/fascia, n (%) | 19 (79) | 4 (17) | 1 (4) | 0 (0) |
| Female genital tract, n (%) | 22 (92) | 1 (4) | 0 (0) | 1 (4) |
| Overall severity according to NIH algorithm, n (%) | 0 (0) | 2 (8) | 7 (29) | 15 (62) |
| Variable | N (%) | |||
| Involved sites, n | ||||
| 1 | 2 | |||
| 2 | 4 | |||
| 3 | 8 | |||
| 4 | 1 | |||
| >4 | 8 | |||
| Chronic GVHD onset type, n (%) | ||||
| De novo | 10 (42) | |||
| Quiescent | 12 (50) | |||
| Progressive | 0 (0) | |||
| Performance score (ECOG), n (%) | ||||
| 0 | 7 (29) | |||
| 1 | 10 (42) | |||
| 2 | 7 (29) | |||
| 3-4 | 0 (0) | |||
| Baseline systemic immune suppression, n (%) | ||||
| CsA | 8 (33) | |||
| Prednisone | 2 (8) | |||
| NIH Consensus score . | None . | Mild . | Moderate . | Severe . |
|---|---|---|---|---|
| Skin, n (%) | 4 (17) | 2 (8) | 12 (50) | 6 (25) |
| Mouth, n (%) | 5 (21) | 9 (37) | 10 (42) | 0 (0) |
| Eyes, n (%) | 14 (58) | 6 (25) | 3 (13) | 1 (4) |
| Gastrointestinal tract, n (%) | 16 (67) | 4 (17) | 4 (17) | 0 (0) |
| Liver, n (%) | 12 (50) | 0 (0) | 5 (21) | 7 (29) |
| Lung, n (%) | 14 (58) | 5 (21) | 4 (17) | 1 (4) |
| Joint/fascia, n (%) | 19 (79) | 4 (17) | 1 (4) | 0 (0) |
| Female genital tract, n (%) | 22 (92) | 1 (4) | 0 (0) | 1 (4) |
| Overall severity according to NIH algorithm, n (%) | 0 (0) | 2 (8) | 7 (29) | 15 (62) |
| Variable | N (%) | |||
| Involved sites, n | ||||
| 1 | 2 | |||
| 2 | 4 | |||
| 3 | 8 | |||
| 4 | 1 | |||
| >4 | 8 | |||
| Chronic GVHD onset type, n (%) | ||||
| De novo | 10 (42) | |||
| Quiescent | 12 (50) | |||
| Progressive | 0 (0) | |||
| Performance score (ECOG), n (%) | ||||
| 0 | 7 (29) | |||
| 1 | 10 (42) | |||
| 2 | 7 (29) | |||
| 3-4 | 0 (0) | |||
| Baseline systemic immune suppression, n (%) | ||||
| CsA | 8 (33) | |||
| Prednisone | 2 (8) | |||
ECOG, Eastern Cooperative Oncology Group.